Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Atezolizumab/bevacizumab and lenvatinib for hepatocellular carcinoma: A comparative analysis in a European real-world cohort.
de Castro T, Welland S, Jochheim L, Leyh C, Shmanko K, Finkelmeier F, Jeliazkova P, Jefremow A, Gonzalez-Carmona MA, Kandulski A, Roessler D, Ben Khaled N, Enssle S, Venerito M, Fründt TW, Schultheiß M, Djanani A, Pangerl M, Maieron A, Wirth TC, Marquardt JU, Greil R, Fricke C, Günther R, Schmiderer A, Bettinger D, Wege H, Scheiner B, Müller M, Strassburg CP, Siebler J, Ehmer U, Waidmann O, Weinmann A, Pinter M, Lange CM, Saborowski A, Vogel A. de Castro T, et al. Among authors: jochheim l. Hepatol Commun. 2024 Nov 4;8(11):e0562. doi: 10.1097/HC9.0000000000000562. eCollection 2024 Nov 1. Hepatol Commun. 2024. PMID: 39495153 Free PMC article.
Atezolizumab/bevacizumab or lenvatinib in hepatocellular carcinoma: Multicenter real-world study with focus on bleeding and thromboembolic events.
Ben Khaled N, Möller M, Jochheim LS, Leyh C, Ehmer U, Böttcher K, Pinter M, Balcar L, Scheiner B, Weich A, Leicht HB, Zarka V, Ye L, Schneider J, Piseddu I, Öcal O, Rau M, Sinner F, Venerito M, Gairing SJ, Förster F, Mayerle J, De Toni EN, Geier A, Reiter FP. Ben Khaled N, et al. Among authors: jochheim ls. JHEP Rep. 2024 Apr 8;6(6):101065. doi: 10.1016/j.jhepr.2024.101065. eCollection 2024 Jun. JHEP Rep. 2024. PMID: 38798717 Free PMC article.
Current use of percutaneous image-guided tumor ablation for the therapy of liver tumors: lessons learned from the registry of the German Society for Interventional Radiology and Minimally Invasive Therapy (DeGIR) 2018-2022.
Zensen S, Bücker A, Meetschen M, Haubold J, Opitz M, Theysohn JM, Schramm S, Jochheim L, Kasper S, Forsting M, Schaarschmidt BM. Zensen S, et al. Among authors: jochheim l. Eur Radiol. 2024 May;34(5):3322-3330. doi: 10.1007/s00330-023-10412-w. Epub 2023 Nov 8. Eur Radiol. 2024. PMID: 37935847 Free PMC article.
Bilobar Radioembolization Carries the Risk of Radioembolization-Induced Liver Disease in the Treatment of Advanced Hepatocellular Carcinoma: Safety and Efficacy Comparison to Systemic Therapy with Atezolizumab/Bevacizumab.
Jeschke M, Ludwig JM, Leyh C, Pabst KM, Weber M, Theysohn JM, Lange CM, Herrmann K, Schmidt HH, Jochheim LS. Jeschke M, et al. Among authors: jochheim ls. Cancers (Basel). 2023 Aug 26;15(17):4274. doi: 10.3390/cancers15174274. Cancers (Basel). 2023. PMID: 37686549 Free PMC article.
Voxel-Based Dosimetry Predicts Hepatotoxicity in Hepatocellular Carcinoma Patients Undergoing Radioembolization with 90Y Glass Microspheres.
Watanabe M, Grafe H, Theysohn J, Schaarschmidt B, Ludwig J, Jochheim L, Jeschke M, Schmidt H, Fendler WP, Moraitis A, Herrmann K, Pomykala KL, Weber M. Watanabe M, et al. Among authors: jochheim l. J Nucl Med. 2023 Jul;64(7):1102-1108. doi: 10.2967/jnumed.122.264996. Epub 2023 Jun 8. J Nucl Med. 2023. PMID: 37290792 Free article.
Atezolizumab Plus Bevacizumab in Patients with Advanced and Progressing Hepatocellular Carcinoma: Retrospective Multicenter Experience.
Sinner F, Pinter M, Scheiner B, Ettrich TJ, Sturm N, Gonzalez-Carmona MA, Waidmann O, Finkelmeier F, Himmelsbach V, De Toni EN, Ben Khaled N, Mohr R, Fründt TW, Kütting F, Bömmel FV, Lieb S, Krug S, Bettinger D, Schultheiß M, Jochheim LS, Best J, Müller C, Keitel V, Venerito M. Sinner F, et al. Among authors: jochheim ls. Cancers (Basel). 2022 Dec 2;14(23):5966. doi: 10.3390/cancers14235966. Cancers (Basel). 2022. PMID: 36497447 Free PMC article.
Ipilimumab and nivolumab in advanced hepatocellular carcinoma after failure of prior immune checkpoint inhibitor-based combination therapies: a multicenter retrospective study.
Roessler D, Öcal O, Philipp AB, Markwardt D, Munker S, Mayerle J, Jochheim LS, Hammer K, Lange CM, Geier A, Seidensticker M, Reiter FP, De Toni EN, Ben Khaled N. Roessler D, et al. Among authors: jochheim ls. J Cancer Res Clin Oncol. 2023 Jul;149(7):3065-3073. doi: 10.1007/s00432-022-04206-8. Epub 2022 Jul 21. J Cancer Res Clin Oncol. 2023. PMID: 35864269 Free PMC article.
13 results